Koers Kalytera Therapeutics Inc Toronto S.E.
Aandelen
CA48349P1036
Biotechnologie & Medisch Onderzoek
Omzet 2019 | - | Omzet 2020 | - | Marktkapitalisatie | 13,65 mln. 18,66 mln. 12,48 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2019 | -21 mln. -28,71 mln. -19,19 mln. | Nettowinst (verlies) 2020 | 4 mln. 5,47 mln. 3,66 mln. | EV/omzet 2019 | - |
Nettoschuld 2019 | 704K 962K 643K | Nettoschuld 2020 | 920K 1,26 mln. 841K | EV/omzet 2020 | - |
K/w-verhouding 2019 |
-0,9
x | K/w-verhouding 2020 |
3,17
x | Werknemers | - |
Dividendrendement 2019 * |
-
| Dividendrendement 2020 |
-
| Vrij verhandelbaar | 99,74% |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 47,96 mld. | |
+0,69% | 42,45 mld. | |
+44,30% | 41,47 mld. | |
+30,52% | 31,6 mld. | |
+22,30% | 28,63 mld. | |
-6,35% | 28,03 mld. | |
+49,25% | 14,56 mld. | |
+49,18% | 14,14 mld. | |
+3,45% | 12,58 mld. |